Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL

(2010) Guangrong Lu et al.   CANCER BIOLOGY & THERAPY

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia

(2010) Massimo Breccia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity

(2010) Øystein Bruserud et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02

(2009) S. LÜ et al.   International Journal of Laboratory Hematology

The potential of proteasome inhibitors in cancer therapy

(2008) Jan Sterz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1

(2008) Xueshi Ye et al.   LEUKEMIA RESEARCH